Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.

Publication

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.

Journal Paper/Review - Apr 1, 2022

Yurchenko Andrey A, Pop Oltin, Ighilahriz Meriem, Padioleau Ismael, Rajabi Fatemeh, Sharpe Hayley J, Poulalhon Nicolas, Dreno Brigitte, Khammari Amir, Delord Marc, Alberti Antonio, Soufir Nadem, Battistella Maxime, Mourah Samia, Bouquet Fanny, Savina Ariel, Besse Andrej, Mendez Lopez Max, Grange Florent, Monestier Sandrine, Mortier Laurent, Meyer Nicolas, Dutriaux Caroline, Robert Caroline, Saiag Philippe, Herms Florian, Lambert Jerome, de Sauvage Frederic J, Dumaz Nicolas, Flatz Lukas, Basset-Seguin Nicole, Nikolaev Sergey

Citation

Yurchenko A, Pop O, Ighilahriz M, Padioleau I, Rajabi F, Sharpe H, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage F, Dumaz N, Flatz L, Basset-Seguin N, Nikolaev S. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. Clin Cancer Res 2022; 28:1422-1432.

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2022; 28

Publication Date

Apr 1, 2022

Issn Electronic

1557-3265

Pages

1422-1432

Brief description/objective

Vismodegib is approved for the treatment of locally advanced basal cell carcinoma (laBCC), but some cases demonstrate intrinsic resistance (IR) to the drug. We sought to assess the frequency of IR to vismodegib in laBCC and its underlying genomic mechanisms.